Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Aditxt Inc (ADTX)

Aditxt Inc (ADTX)
3.00 x 3 3.13 x 1
Pre-market by (Cboe BZX)
2.88 unch (unch) 04/11/25 [NASDAQ]
3.00 x 3 3.13 x 1
Pre-market 2.98 +0.10 (+3.47%) 06:44 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.75
Day High
3.09
Open 2.85
Previous Close 2.88 2.88
Volume 547,500 547,500
Avg Vol 8,255,765 8,255,765
Stochastic %K 6.05% 6.05%
Weighted Alpha -99.53 -99.53
5-Day Change -1.85 (-39.11%) -1.85 (-39.11%)
52-Week Range 2.53 - 32,100.00 2.53 - 32,100.00
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 164
  • Shares Outstanding, K 57
  • Annual Sales, $ 130 K
  • Annual Income, $ -34,450 K
  • EBIT $ -30 M
  • EBITDA $ -26 M
  • 60-Month Beta 1.55
  • Price/Sales 1.22
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.53 +13.83%
on 04/09/25
Period Open: 15.00
14.50 -80.14%
on 03/12/25
-12.12 (-80.80%)
since 03/11/25
3-Month
2.53 +13.83%
on 04/09/25
Period Open: 42.47
51.92 -94.45%
on 01/16/25
-39.59 (-93.22%)
since 01/10/25
52-Week
2.53 +13.83%
on 04/09/25
Period Open: 31,500.00
32,100.00 -99.99%
on 04/12/24
-31,497.12 (-99.99%)
since 04/11/24

Most Recent Stories

More News
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025

APLIF : 0.0218 (+0.93%)
APLI.TO : 0.0300 (+20.00%)
ADTX : 2.88 (unch)
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update

APLIF : 0.0218 (+0.93%)
APLI.TO : 0.0300 (+20.00%)
ADTX : 2.88 (unch)
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

SLDB : 2.70 (+1.12%)
SLRN : 2.23 (+3.72%)
ESLA : 0.8690 (-4.51%)
CADL : 4.97 (+4.19%)
ADTX : 2.88 (unch)
Microcap Biotech Aditxt Rallies Retail Interest Ahead Of CEO’s Fireside Chat: What’s On Investors’ Radar?

The event will cover Adimune, Inc., which focuses on autoimmunity treatments, and subsidiary Pearsanta's planned IPO in 2025.

VXF : 160.66 (+1.55%)
ADTX : 2.88 (unch)
Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome

Aditxt®, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that modulate and monitor the immune system, today announces that...

ADTX : 2.88 (unch)
Aditxt (NASDAQ: ADTX) Closes on $1.9M Registered Direct Offering

Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced that it has closed on its previously announced registered...

ADTX : 2.88 (unch)
Aditxt Announces Closing of $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced...

ADTX : 2.88 (unch)
Aditxt Inc. (NASDAQ: ADTX) Registered Direct Offering Expected to Total $1.9M

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has entered into a definitive agreement. The company...

ADTX : 2.88 (unch)
Aditxt (NASDAQ: ADTX) Inks Agreement for 50% Ownership of Global Response Aid

Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, has signed an asset purchase agreement with Cellvera Ltd. According...

ADTX : 2.88 (unch)
Aditxt Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that...

ADTX : 2.88 (unch)

Business Summary

Aditx Therapeutics Inc. is a life sciences company. It engages in developing biotechnologies specifically focused on health of the immune system through immune monitoring and reprogramming. Aditx Therapeutics Inc. is based in LOMA LINDA, CA.

See More

Key Turning Points

3rd Resistance Point 3.40
2nd Resistance Point 3.25
1st Resistance Point 3.06
Last Price 2.88
1st Support Level 2.72
2nd Support Level 2.57
3rd Support Level 2.38

See More

52-Week High 32,100.00
Fibonacci 61.8% 19,838.77
Fibonacci 50% 16,051.26
Fibonacci 38.2% 12,263.76
Last Price 2.88
52-Week Low 2.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar